173 related articles for article (PubMed ID: 19894105)
21. Properties of HPMA copolymer-doxorubicin conjugates with pH-controlled activation: effect of polymer chain modification.
Chytil P; Etrych T; Konák C; Sírová M; Mrkvan T; Ríhová B; Ulbrich K
J Control Release; 2006 Sep; 115(1):26-36. PubMed ID: 16899320
[TBL] [Abstract][Full Text] [Related]
22. Tumor-targeted micelle-forming block copolymers for overcoming of multidrug resistance.
Braunová A; Kostka L; Sivák L; Cuchalová L; Hvězdová Z; Laga R; Filippov S; Černoch P; Pechar M; Janoušková O; Šírová M; Etrych T
J Control Release; 2017 Jan; 245():41-51. PubMed ID: 27871991
[TBL] [Abstract][Full Text] [Related]
23. The structure of polymer carriers controls the efficacy of the experimental combination treatment of tumors with HPMA copolymer conjugates carrying doxorubicin and docetaxel.
Šírová M; Strohalm J; Chytil P; Lidický O; Tomala J; Říhová B; Etrych T
J Control Release; 2017 Jan; 246():1-11. PubMed ID: 27940304
[TBL] [Abstract][Full Text] [Related]
24. Bloodstream Stability Predetermines the Antitumor Efficacy of Micellar Polymer-Doxorubicin Drug Conjugates with pH-Triggered Drug Release.
Chytil P; Šírová M; Kudláčová J; Říhová B; Ulbrich K; Etrych T
Mol Pharm; 2018 Sep; 15(9):3654-3663. PubMed ID: 29543465
[TBL] [Abstract][Full Text] [Related]
25. Polymeric anticancer drugs with pH-controlled activation.
Ulbrich K; Etrych T; Chytil P; Pechar M; Jelinkova M; Rihova B
Int J Pharm; 2004 Jun; 277(1-2):63-72. PubMed ID: 15158969
[TBL] [Abstract][Full Text] [Related]
26. Star structure of antibody-targeted HPMA copolymer-bound doxorubicin: a novel type of polymeric conjugate for targeted drug delivery with potent antitumor effect.
Kovár M; Strohalm J; Etrych T; Ulbrich K; Ríhová B
Bioconjug Chem; 2002; 13(2):206-15. PubMed ID: 11906257
[TBL] [Abstract][Full Text] [Related]
27. HPMA copolymer conjugates of paclitaxel and docetaxel with pH-controlled drug release.
Etrych T; Sírová M; Starovoytova L; Ríhová B; Ulbrich K
Mol Pharm; 2010 Aug; 7(4):1015-26. PubMed ID: 20518512
[TBL] [Abstract][Full Text] [Related]
28. Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer-doxorubicin conjugates to human colon cancer cells.
David A; Kopecková P; Minko T; Rubinstein A; Kopecek J
Eur J Cancer; 2004 Jan; 40(1):148-57. PubMed ID: 14687799
[TBL] [Abstract][Full Text] [Related]
29. Novel star HPMA-based polymer conjugates for passive targeting to solid tumors.
Etrych T; Strohalm J; Chytil P; Říhová B; Ulbrich K
J Drug Target; 2011 Dec; 19(10):874-89. PubMed ID: 21978286
[TBL] [Abstract][Full Text] [Related]
30. HPMA copolymer conjugates with reduced anti-CD20 antibody for cell-specific drug targeting. I. Synthesis and in vitro evaluation of binding efficacy and cytostatic activity.
Etrych T; Strohalm J; Kovár L; Kabesová M; Ríhová B; Ulbrich K
J Control Release; 2009 Nov; 140(1):18-26. PubMed ID: 19632282
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma.
Minko T; Kopecková P; Kopecek J
Int J Cancer; 2000 Apr; 86(1):108-17. PubMed ID: 10728603
[TBL] [Abstract][Full Text] [Related]
32. Anti-Lymphoma Efficacy Comparison of Anti-Cd20 Monoclonal Antibody-Targeted and Non-Targeted Star-Shaped Polymer-Prodrug Conjugates.
Lidický O; Janoušková O; Strohalm J; Alam M; Klener P; Etrych T
Molecules; 2015 Nov; 20(11):19849-64. PubMed ID: 26556320
[TBL] [Abstract][Full Text] [Related]
33. Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate.
Omelyanenko V; Kopecková P; Gentry C; Kopecek J
J Control Release; 1998 Apr; 53(1-3):25-37. PubMed ID: 9741911
[TBL] [Abstract][Full Text] [Related]
34. Synergistic enhancement of anticancer therapeutic efficacy of HPMA copolymer doxorubicin conjugates via combination of ligand modification and stimuli-response srategies.
Li L; Zhou M; Huang Y
Int J Pharm; 2018 Jan; 536(1):450-458. PubMed ID: 29237570
[TBL] [Abstract][Full Text] [Related]
35. In vitro and in vivo effect of HPMA copolymer-bound doxorubicin targeted to transferrin receptor of B-cell lymphoma 38C13.
Kovár M; Strohalm J; Ulbrich K; Ríhová B
J Drug Target; 2002 Feb; 10(1):23-30. PubMed ID: 11996083
[TBL] [Abstract][Full Text] [Related]
36. Tumor targeting by pH-sensitive, biodegradable, cross-linked N-(2-hydroxypropyl) methacrylamide copolymer micelles.
Zhou Z; Li L; Yang Y; Xu X; Huang Y
Biomaterials; 2014 Aug; 35(24):6622-35. PubMed ID: 24814427
[TBL] [Abstract][Full Text] [Related]
37. Comparison of active and passive targeting of doxorubicin for somatostatin receptor 2 positive tumor models by octreotide-modified HPMA copolymer-doxorubicin conjugates.
He S; Zhou Z; Li L; Yang Q; Yang Y; Guan S; Zhang J; Zhu X; Jin Y; Huang Y
Drug Deliv; 2016; 23(1):285-96. PubMed ID: 24865288
[TBL] [Abstract][Full Text] [Related]
38. Highly effective anti-tumor nanomedicines based on HPMA copolymer conjugates with pirarubicin prepared by controlled RAFT polymerization.
Randárová E; Nakamura H; Islam R; Studenovský M; Mamoru H; Fang J; Chytil P; Etrych T
Acta Biomater; 2020 Apr; 106():256-266. PubMed ID: 32058082
[TBL] [Abstract][Full Text] [Related]
39. Starlike vs. classic macromolecular prodrugs: two different antibody-targeted HPMA copolymers of doxorubicin studied in vitro and in vivo as potential anticancer drugs.
Jelínková M; Strohalm J; Etrych T; Ulbrich K; Ríhová B
Pharm Res; 2003 Oct; 20(10):1558-64. PubMed ID: 14620507
[TBL] [Abstract][Full Text] [Related]
40. Synergistic effect of EMF-BEMER-type pulsed weak electromagnetic field and HPMA-bound doxorubicin on mouse EL4 T-cell lymphoma.
Říhová B; Etrych T; Šírová M; Tomala J; Ulbrich K; Kovář M
J Drug Target; 2011 Dec; 19(10):890-9. PubMed ID: 21981636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]